Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressional 45-day review period included in reg reform measure approved by Senate Govt. Affairs Cmte.

Executive Summary

CONGRESSIONAL 45-DAY REVIEW OF AGENCY RULES INCLUDED IN REG REFORM BILL approved 15-0 by the Senate Governmental Affairs Committee during a March 23 markup. The congressional review provision is taken largely from the "Comprehensive Regulatory Reform Act" (S 343) as reported out by the Senate Judiciary/Oversight & Courts Subcommittee March 14, although the legislation reported out of Government Affairs is based on Committee Chairman Roth's (R-Del.) own regulatory reform bill, S 291.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel